Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have earned an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $41.33.

A number of brokerages recently issued reports on GMAB. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday. Truist Financial reduced their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its position in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC lifted its stake in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC grew its holdings in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares in the last quarter. Barclays PLC increased its position in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC increased its position in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $19.24 on Friday. The company has a 50 day simple moving average of $20.72 and a 200-day simple moving average of $21.70. The company has a market capitalization of $12.73 billion, a P/E ratio of 11.06, a P/E/G ratio of 2.65 and a beta of 0.98. Genmab A/S has a 1 year low of $18.48 and a 1 year high of $30.50.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.